Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Ota, Japan Clinical Trials

A listing of Ota, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (67) clinical trials

Vincristine Dactinomycin and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Embryonal Rhabdomyosarcoma

OBJECTIVES: - Determine the progression-free survival rate in patients with low-risk embryonal rhadomyosarcoma treated with a shortened treatment schedule of vincristine, dactinomycin, and cyclophosphamide with or without radiotherapy. OUTLINE: Patients receive vincristine IV, dactinomycin IV, and cyclophosphamide IV. Patients may also undergo radiotherapy. Treatment repeats every 3 weeks for up …

Phase

0.7 miles

Learn More »

Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients

The purpose of this study is to support the dose selection for future studies by evaluating efficacy and safety of different QBW251 doses in COPD patients with chronic bronchitis and a history of exacerbations, compared to placebo, when added to a triple combination therapy of LABA, LAMA and ICS with …

Phase

3.2 miles

Learn More »

A Study of TAK-994 in Participants With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 [NT1] or Narcolepsy Type 2 [NT2])

The drug being tested in this study is called TAK-994. The study will enroll up to approximately 126 participants. Participants will be randomly assigned (by chance, like flipping a coin) in 2:1 ratio to one of the 6 treatment Cohorts: Cohort 1, NT1 Participants: TAK-994 Dose Level 1 Cohort 2, …

Phase

3.24 miles

Learn More »

Evaluation of S-600918 in Adults With Refractory Chronic Cough

The primary objective of this study is to determine the optimal dose of S-600918 in patients with refractory chronic cough by evaluating the change from baseline in 24-hour cough frequency (coughs per hour) with S-600918 compared with placebo.

Phase

3.28 miles

Learn More »

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

To evaluate efficacy, safety and pharmacokinetic profile of asciminib 40mg+imatinib or asciminib 60mg+imatinib versus continued imatinib and versus nilotinib in pre-treated patients with Chronic Myeloid Leukemia in chronic phase (CML-CP)

Phase

3.41 miles

Learn More »

A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients

The patients who complete 16 weeks of treatment in ZPL389 core study will be eligible to participate and patients will be advised to apply TCS and / or TCI concomitantly or intermittently along with once daily oral administration of ZPL389.

Phase

3.41 miles

Learn More »

An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion

Anemia is considered to be one of the most prevalent cytopenias in patients who have myelodysplastic syndromes, an umbrella term used to describe disorders relating to the ineffective production of red blood cells, white blood cells, and/or platelets. Ranging in severity from mild (asymptomatic) to severe, anemia can result in …

Phase

3.41 miles

Learn More »

Efficacy and Safety Study of HLCM051(MultiStem ) for Pneumonic Acute Respiratory Distress Syndrome

The objectives of this clinical study are as follows(ARDS caused by pneumonia cohort): Primary objective To investigate the efficacy of HLCM051 in patients with ARDS caused by pneumonia Secondary objective To confirm the safety of HLCM05 in patients with ARDS caused by pneumonia Exploratory objective To investigate changes of biomarkers …

Phase

3.41 miles

Learn More »

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

All subjects will receive a SC dose of either investigational product or placebo as the first dose on day 1. Subjects who are determined to be non-responders in Part A will receive tezepelumab SC Q2W following completion of all week 16 study activities. Nonresponders are defined as those subjects who …

Phase

3.41 miles

Learn More »

A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

This multicenter study is being conducted to provide additional PF-06826647 safety and tolerability data, and to further explore the clinical efficacy of PF-06826647 in the treatment of moderate to severe plaque psoriasis. Additionally, the study is intended to enable selection of oral dose and dosing regimen for the future clinical …

Phase

3.41 miles

Learn More »